GHK-Cu
Also known as: GHK, glycyl-L-histidyl-L-lysine, Gly-His-Lys, copper peptide, copper tripeptide complex, glycyl-L-histidyl-L-lysine-Cu(2+), glycyl-L-histidyl-L-lysine copper(II) complex, GHK-Cu2+, Copper tripeptide, Glycyl-L-histidyl-L-lysine-Cu(II)
Endogenous copper-binding tripeptide / matrikine / cosmeceutical peptide
What it is
GHK-Cu is a copper peptide widely used in skincare for wound healing, skin rejuvenation, and anti-aging. It works by delivering copper to skin cells and activating the processes the body uses to repair and rebuild tissue. Not FDA-approved as a drug; extensively used in cosmetics and widely studied.
The scientific side
GHK (glycyl-L-histidyl-L-lysine) is a naturally occurring tripeptide found in human plasma, saliva, urine, and tissue that declines with age. It forms a complex with copper(II) ions (GHK-Cu), which shares copper affinity similar to the transport site on albumin. GHK-Cu activates tissue remodeling through multiple mechanisms: (1) chemoattraction of macrophages, mast cells, and capillary endothelial cells to sites of injury; (2) anti-inflammatory actions including suppression of free radicals, thromboxane formation, TNF-α, and TGF-β1, while increasing superoxide dismutase activity; (3) stimulation of collagen, elastin, glycosaminoglycan, VEGF, FGF-2, NGF, and other growth factor synthesis; (4) promotion of angiogenesis, fibroblast and keratinocyte proliferation, and nerve outgrowth. GHK-Cu modulates metalloproteinase and anti-protease activity. At the molecular level, GHK-Cu directly binds and activates SIRT1, which deacetylates FoxO3a (reducing protein degradation), Nrf2 (reducing oxidative stress), and increases PGC-1α expression to promote mitochondrial function. GHK-Cu suppresses the JAK1 and STAT3 pathways, modulates PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK signaling, and has been found to up- and downregulate at least 4,000 human genes. Copper ions facilitated by GHK-Cu activate copper-dependent proteins such as lysyl oxidase (LOX) via ATOX1-mediated transport into the Golgi apparatus, promoting collagen crosslinking and extracellular matrix remodeling. GHK also chelates and reduces copper redox activity, preventing copper- and zinc-induced protein aggregation and cell death in vitro. Copper-free GHK (apo-GHK) retains some biological effects, including increased keratinocyte proliferation and integrin expression, suggesting partial activity independent of copper coordination.
Class: Endogenous copper-binding tripeptide / matrikine / cosmeceutical peptide
At a glance
| What it is | A natural tripeptide (glycine-histidine-lysine) bound to copper, first found in human blood in 1973. |
|---|---|
| FDA status | Not approved as a drug. A common cosmetic ingredient; FDA put injectable GHK-Cu on its compounding safety-risk list in 2023. |
| Used for | Skin and hair products; injected for skin, healing and anti-aging, without human injection studies. |
| Human evidence | Topical skin studies only. No published human injection study. |
| Copper per dose | 1-2 mg carries about 160-320 micrograms of copper, under the 900 microgram daily RDA and far under the 10 mg upper limit. |
| Sport | Not listed on the 2026 WADA Prohibited List. |
What is GHK-Cu?
GHK-Cu is a three-amino-acid peptide, glycyl-L-histidyl-L-lysine, carrying a copper ion. It occurs naturally in human blood; Loren Pickart first described it in 1973 as a factor in human serum that kept liver cells alive longer in culture.
It is best known as "copper peptide" in skin and hair products. Injection is a separate, newer grey-market use.
How does it work?
GHK binds copper tightly and is thought to deliver it to tissues, where copper is needed by enzymes involved in collagen, antioxidant defense and wound repair. In cell and gene-expression studies, GHK changed the activity of many genes linked to tissue repair and inflammation.
Most of this evidence is from cell culture, gene databases and animals. How much reaches tissues after an injection, and what it does there in people, is not known.
Pharmacokinetics
| Half-life | Not published for injected GHK-Cu |
|---|---|
| Metabolism | Not characterized in humans |
| Clearance | Not characterized in humans |
| Route | Mainly topical (creams, serums); injection is unstudied |
Is it FDA-approved?
No. GHK-Cu is not an approved drug for any use, though it is widely sold in cosmetics.
In September 2023, FDA placed GHK-Cu for injectable routes in Category 2 for 503A compounding, writing: "Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations." As of April 2026 it is listed under "nominated but withdrawn". It has not had an advisory committee vote.
- WADA: Not listed on the 2026 WADA Prohibited List
History
Pickart's 1973 finding, a serum tripeptide that prolonged the survival of liver cells, led to decades of work on GHK in wound healing and skin. Its main commercial path became cosmetics, where copper peptides are common in creams and serums.
Injecting GHK-Cu is recent and unregulated. It is sold as a research peptide, which is what prompted FDA's 2023 compounding safety listing for injectable routes.
Regulatory timeline
- September 29, 2023FDA places GHK-Cu (for injectable routes) in Category 2 for 503A compounding, citing immunogenicity and limited human data. Source
- April 2026FDA's page lists GHK-Cu under "nominated but withdrawn". Source
- As of October 2026Not an approved drug, and not voted on by FDA's Pharmacy Compounding Advisory Committee. Source
Side effects
There are no human injection data, so injection side effects are unknown. FDA's concern is immune reactions from aggregates and impurities, not the copper.
The copper in a typical dose is small. GHK-Cu is about 16% copper by weight, so 1-2 mg carries about 160-320 micrograms, below the 900 microgram adult RDA and well under the 10 mg/day upper limit set to prevent liver damage. People with Wilson disease or other copper-handling disorders should avoid it.
Who should not use it
- No established contraindications for injection: it has never been studied that way.
- Wilson disease or other copper-handling disorders: avoid added copper.
- Pregnancy and breastfeeding: not studied for injection.
No published human injection study; human data are from topical products.
What does the research show?
Human studies are of topical products. In a trial after CO2 laser resurfacing, GHK-Cu skin care products did not reduce redness more than standard care, though patient satisfaction was higher.
Reviews describe wound-healing, anti-inflammatory and skin-remodeling effects in cell and animal studies, mostly from Pickart's group. No published human trial has tested injected GHK-Cu.
Studied for
- Topical skin care, including after laser resurfacing (human)
- Wound healing and tissue repair (cell and animal studies)
- Gene expression in tissue repair (database studies)
FAQ
Has GHK-Cu been tested as an injection in humans?
No published study has. All human data are from creams and serums.
Sources: [3]
Is the copper in GHK-Cu a concern?
Not at typical doses: 1-2 mg contains about 160-320 micrograms of copper, under the 900 microgram RDA and the 10 mg/day upper limit. People with copper-handling disorders such as Wilson disease are the exception.
Sources: [6]
What has FDA said about GHK-Cu?
FDA wrote that compounded injectable GHK-Cu "may pose risk for immunogenicity" and that "there are limited data in humans to inform safety-related considerations."
Sources: [5]
Where does GHK-Cu come from?
It occurs naturally in human blood; it was first described in 1973 as a serum factor that prolonged liver cell survival.
Sources: [1]
Is GHK-Cu banned in sport?
Not listed on the 2026 WADA Prohibited List. Athletes should still check with their anti-doping organization.
Sources: [8]
Citations
- Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol 1973. PMID 4349963
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018. PMID 29986520
- Mateescu DM, et al. GHK-Cu as a bioactive metallopeptide and drug-delivery cargo: coordination chemistry, formulation science, therapeutic evidence, and a translational roadmap. Pharmaceutics 2026. PMID 42797253
- FDA: the same page as archived September 28, 2024. web.archive.org/web/20240928064141/https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- National Academies: Dietary Reference Intakes, copper (RDA 900 micrograms/day; UL 10 mg/day based on liver damage). nap.edu/read/10026/chapter/9
- Miller TR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg 2006. PMID 16847171
- World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf
Sources
- Pickart 1973. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol 1973. pubmed.ncbi.nlm.nih.gov/4349963
- Pickart 2018. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018. pubmed.ncbi.nlm.nih.gov/29986520
- Mateescu 2026. Mateescu DM, et al. GHK-Cu as a bioactive metallopeptide and drug-delivery cargo: coordination chemistry, formulation science, therapeutic evidence, and a translational roadmap. Pharmaceutics 2026. pubmed.ncbi.nlm.nih.gov/42797253
- Miller 2006. Miller TR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg 2006. pubmed.ncbi.nlm.nih.gov/16847171
- National Academies. National Academies: Dietary Reference Intakes, copper (RDA 900 micrograms/day; UL 10 mg/day based on liver damage). nap.edu/read/10026/chapter/9
- FDA. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- FDA (2024 archive). FDA: the same page as archived September 28, 2024. web.archive.org/web/20240928064141/https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- FDA PCAC, July 2026. FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee (agenda). fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- WADA. World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf
Administration & storage
- Administration
- Intraperitoneal injection (IP) — used in aged mice at 15 mg/kg (PMID: 42245779)Intranasal (IN) administration — used in aged mice and 5xFAD mice at 15 mg/kg (PMID: 4076691942245779)Intracutaneous injection — Gly-His-Lys-D-Ala at 0.5 µg/kg in ratsadministered around wound site (PMID: 38345677)Topical/transdermal application — reported for cosmetic and wound care contexts (PMID: 2623673016847171)Microneedle-assisted transdermal delivery — used in in vitro and porcine models (PMID: 25690343)Injectable filler (hydroxyapatite microsphere carriersubcutaneous/soft tissue) — in mice and rats (PMID: 40716276)
- Storage
- No specific storage conditions for GHK-Cu are described in the reviewed abstracts. General formulation challenges noted include hydrophilicity and instability of peptide ingredients. Requires manual verification from manufacturer or compounding guidelines.
- Cautions
- GHK-Cu is not FDA-approved as a drug; human safety data from rigorous clinical trials are scarce across all routes of administration.,Most human evidence comes from small or incompletely characterized cosmetic studies; no large-scale controlled human safety trials have been published in the reviewed literature.,In vitro keratinocyte studies found GHK-Cu was not cytotoxic and did not significantly upregulate skin irritation biomarkers at tested concentrations; CuCl2 and Cu(OAc)2 showed higher irritancy potential than GHK-Cu. However, skin irritation potential at higher concentrations or in vivo has not been fully characterized.,GHK-Cu demonstrated biphasic dose-response in vitro (maximal GAG stimulation at 10⁻⁹ to 10⁻⁸ M; stimulation declined at higher concentrations), suggesting potential concentration-dependent effects.,Sterile technique is essential for any injectable formulation to prevent contamination; compounded peptides may lack the quality controls of approved pharmaceuticals.,GHK-Cu slightly inhibited alkaline phosphatase activity and osteocalcin production in osteoblastic cells in vitro, suggesting potential adverse effects on osteoblast differentiation at certain concentrations.
Legal & regulatory status
Not FDA-approved as a drug; most applications remain unapproved. Multiple review articles note GHK-Cu is not FDA-approved and lacks rigorous clinical trial validation. One review notes GHK-Cu is categorized among…
Not listed on the 2026 WADA Prohibited List.
Not stated in reviewed literature — requires manual verification
What it's studied for
- Wound healing and skin repair Mixed
- 13-patient RCT of GHK-Cu skin care products after CO2 laser resurfacing found no statistically significant reduction in erythema or objective improvement in wrinkles, but patient-reported satisfaction was significantly higher in the GHK-Cu group (P=0.04). PMID 16847171 Miller TR et al. Arch Facial Plast Surg. 2006.
- GHK-Cu-liposomes promoted HUVEC proliferation (33.1% increased rate), upregulated VEGF and FGF-2, and shortened wound healing time to 14 days post-injury in a mouse scald model, outperforming free GHK-Cu for angiogenesis. PMID 28370978 Wang X et al. Wound Repair Regen. 2017.
- In vitro study: GHK-Cu (1×10⁻⁹ mol/L) accelerated growth of normal and irradiated fibroblasts; irradiated fibroblasts treated with GHK-Cu approximated population-doubling time of normal controls and produced more FGF-2 and VEGF early after exposure. PMID 15655171 Pollard JD et al. Arch Facial Plast Surg. 2005.
- Review: GHK accelerates wound healing of skin, hair follicles, GI tract, boney tissue, and dog foot pads; induces systemic wound healing in rats, mice, and pigs; and in cosmetic products tightens skin, improves elasticity, reduces fine lines, wrinkles, photodamage, and hyperpigmentation. PMID 26236730 Pickart L et al. BioMed Res Int. 2015.
- Gly-His-Lys-D-Ala (0.5 µg/kg, intracutaneous daily injection) in Wistar rats promoted wound regeneration, increased fibroblastic cells and macrophages, decreased granulocytes, and promoted wound contraction on day 30. PMID 38345677 Rakhmetova KK et al. Bull Exp Biol Med. 2024.
- Systematic review (64 studies, 2005–2026): preclinical data consistently support GHK-Cu in matrix remodeling, epithelial repair, anti-inflammatory/redox regulation, and angiogenesis; clinical evidence remains sparse and fragmented; no adequately powered human RCT of microneedle-delivered GHK-Cu published as of review. PMID 42787770 Najafi N et al. Arch Intern Med Res. 2026.
- Systematic review (20 studies: 18 preclinical, 2 RCTs): GHK-Cu enhanced ECM synthesis, modulated MMP activity, promoted angiogenesis, suppressed TGF-β and IL-6; clinically improved patient-reported satisfaction after laser resurfacing and reduced wrinkle volume vs. controls; advanced delivery systems (microneedles, lip PMID 42619529 Mokhtar J et al. Aesthetic Surg J. 2026.
- Anti-aging and skin rejuvenation (topical/cosmeceutical) Mixed
- GHK-Cu combined with low-molecular-weight HA at 1:9 ratio elevated collagen IV synthesis 25.4-fold in fibroblast cell test and 2.03-fold in ex-vivo skin test, demonstrating synergy on collagen IV at the dermal-epidermal junction. PMID 37062921 Jiang F et al. J Cosmet Dermatol. 2023.
- Review: GHK stimulates collagen, elastin, and glycosaminoglycan synthesis; supports dermal fibroblast function; improves tissue repair in skin, lung, liver, bone, and stomach; possesses anti-cancer and anti-inflammatory activities; modulates thousands of human genes. PMID 29986520 Pickart L & Margolina A. Int J Mol Sci. 2018.
- Review: based on cellular studies, GHK can be considered an anti-wrinkle ingredient; GHK-Cu and Pal-GHK are widely used in anti-wrinkle products; clinical studies are surprisingly absent despite broad market use; permeation enhancement via microneedles, CPPs, and chemical modification is promising. PMID 39963574 Mortazavi SM et al. BioImpacts. 2025.
- Review: tripeptide (GHK-Cu) formulation shown to offer improved healing and clinical outcomes in conjunction with resurfacing and cryolipolysis, and benefit for cutaneous rejuvenation. PMID 33938433 Wang JV et al. Skinmed. 2021.
- Anti-inflammatory and antioxidant effects Animal studies only
- GHK-Cu reduced neutrophil and macrophage migration, suppressed pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), increased IL-10, reduced NO and ROS, improved SOD activity, and downregulated the JAK1 pathway in zebrafish larvae acute inflammation models (CuSO4 and LPS). PMID 41997403 Hu J et al. Eur J Pharmacol. 2026.
- GHK-Cu attenuated lung inflammation and fibrosis in a silicosis mouse model by binding PRDX6 and inhibiting oxidative stress in alveolar macrophages, without significant systemic toxicity. PMID 38879894 Bian Y et al. Redox Biol. 2024.
- TJE-GHK-Cu complex (6:4 ratio) synergistically suppressed Th2 cytokines (IL-4, IL-5, IL-10, IL-13), AD-related chemokines, and IgE production in TNF-α/IFN-γ-stimulated HaCaT cells, and promoted keratinocyte migration. PMID 42510549 Jeon S et al. Antioxidants. 2026.
- Skeletal muscle dysfunction / COPD-related sarcopenia Mixed
- Plasma GHK levels were significantly lower in COPD patients than healthy controls (70.27±38.87 vs 133.0±54.54 ng/mL, P=0.009) and correlated with pectoralis muscle area, TNF-α, and SOD2. GHK-Cu (0.2 and 2 mg/kg) in CS-exposed C57BL/6 mice reduced muscle mass loss and improved grip strength via SIRT1 activation. Human p PMID 36905132 Deng M et al. J Cachexia Sarcopenia Muscle. 2023.
- Airway remodeling in asthma Mixed
- Plasma GHK levels were significantly lower in asthma patients than controls and correlated with FAO. GHK-Cu administration in OVA-induced mice alleviated peribronchial collagen deposition, mucus secretion, and epithelial-mesenchymal transition via SIRT1 activation and decreased TGF-β1. Human data were observational. PMID 37257226 Zhang Q et al. Biomed Pharmacother. 2023.
- Pulmonary fibrosis / silicosis Animal studies only
- GHK-Cu attenuated lung inflammation and fibrosis in a crystalline silica mouse model by binding PRDX6 and reducing oxidative stress in alveolar macrophages, without significant systemic toxicity. PMID 38879894 Bian Y et al. Redox Biol. 2024.
- Ulcerative colitis / inflammatory bowel disease Animal studies only
- GHK-Cu alleviated DSS-induced UC in mice: reduced weight loss, improved disease activity index, suppressed TNF-α/IL-6/IL-1β, increased ZO-1 and Occludin, and promoted mucosal healing via the SIRT1/STAT3 pathway. PMID 40672369 Mao S et al. Front Pharmacol. 2025.
- In vitro study: GHK-Cu-loaded Zn-pectinate microparticles compression-coated with HPC showed delayed release (lag time ~6 h) suitable for colonic delivery to inhibit MMP and promote TIMP secretion for IBD mucosal healing. PMID 21457130 Ugurlu T et al. Drug Dev Ind Pharm. 2011.
- Neuroprotection / neurodegenerative disease Animal studies only
- Intranasal GHK-Cu (15 mg/kg, 3×/week for 3 months) in 5xFAD mice delayed cognitive impairment, reduced amyloid plaques, and lowered MCP1-mediated inflammation in frontal cortex and hippocampus. PMID 40766919 Tucker M et al. Aging Pathobiol Ther. 2024.
- In aged C57BL/6J mice (20–21 months), GHK-Cu 15 mg/kg IP (5 days) or IN (8 weeks) both improved hippocampal-dependent escape learning but via divergent molecular programs; IN treatment increased synaptophysin and decreased GFAP in females, IP reduced TGF-β and MCP-1 in males. PMID 42245779 Mazzola J et al. Res Sq. 2026.
- GHK (copper-free) prevented copper- and zinc-induced CNS cell death in vitro, reduced copper redox activity, prevented and reversed BSA aggregation, and attenuated copper-enhanced paraquat toxicity. PMID 38599632 Min JH et al. Metallomics. 2024.
- Review: GHK-Cu proposed as therapeutic agent against age-associated neurodegeneration and cognitive decline based on antioxidant, anti-inflammatory, copper-chelating, and gene-regulatory properties; noted as having a long history of safe use in wound healing and antiaging skin care. PMID 22666519 Pickart L et al. Oxid Med Cell Longev. 2012.
- Anti-aging (lifespan/longevity models) Animal studies only
- GHK-Cu significantly extended lifespan of C. elegans, improved stress resistance, motility, and pharyngeal function, reduced lipofuscin accumulation, preserved mitochondrial membrane potential, promoted mitochondrial fusion, and activated DAF-16 and SKN-1 pathways. PMID 42084774 Wen H et al. Biogerontology. 2026.
- Osteoblast biology / bone tissue In vitro only
- GHK:Cu coating increased attachment of rat calvaria and human trabecular osteoblastic cells; however, GHK:Cu slightly inhibited basal and 1,25(OH)2D-induced alkaline phosphatase activity and osteocalcin production in rat and human osteoblastic cells in vitro. PMID 8747089 Godet D & Marie PJ. Cell Mol Biol. 1995.
- Fascia regeneration Animal studies only
- A Golgi-targeted system using GHK-Cu as copper source combined with LNP-ATOX1 mRNA promoted collagen alignment and neovascularization, elevated LOX activity 1.78-fold over control, and improved fascia regeneration in a rabbit fascia defect model. PMID 41476424 Wang R et al. J Control Release. 2026.
- Hair growth promotion Animal studies only
- An ionic liquid microemulsion (IL-M) system improved local delivery of GHK-Cu approximately 3-fold vs. conventional formulation in mice and was effective for hair growth promotion, activating Wnt/β-catenin signaling and VEGF expression; described as a powerful hair growth promoter with minimal side effects compared wit PMID 38026438 Liu T et al. Bioact Mater. 2024.
- Diabetic wound healing Animal studies only
- GOX-loaded hydrogel with GHK-Cu enabled cascade catalysis: GOX oxidized glucose (reducing hyperglycemia, generating H2O2), GHK-Cu Cu ions decomposed H2O2 (CAT-like) releasing oxygen, alleviating hypoxia, with additional antibacterial, tissue repair, antioxidant, and angiogenesis effects confirmed in vitro and in vivo. PMID 42404628 Huang ZJ et al. Mater Today Bio. 2026.
- Musculoskeletal conditions (orthopaedic/sports medicine) Animal studies only
- Narrative review: GHK-Cu showed promise in wound healing and anti-inflammatory effects, but no clinical data support its use for musculoskeletal conditions. PMID 41476424 Mayfield CK et al. Am J Sports Med. 2026.
- Scoping review: 67% of identified publications on emerging peptides (including GHK-Cu) used preclinical animal models; human clinical studies were limited, lacked robust controls, and revealed modest improvements at best; peptide supplements should not currently be recommended as replacement or adjunct for orthopaedic PMID 42578445 Tewari K et al. Am J Sports Med. 2026.
Protocol
1-2 mg subcutaneous injection, daily. Cycle: 4-8 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Not specified (in vivo, C57BL/6 mice) | 0.2 mg/kg and 2 mg/kg | Not explicitly stated for the full treatment course; assessed across multiple timepoints | animal | Research PMID 36905132 |
| Intranasal | 15 mg/kg | 3 months (3 times per week) | animal | Research PMID 40766919 |
| Intraperitoneal (IP) or intranasal (IN) | 15 mg/kg | IP: 5 days; IN: 8 weeks | animal | Research PMID 42245779 |
| In vitro (serum-free media) | 1 × 10⁻⁹ mol/L | Not specified | in_vitro | Research PMID 15655171 |
| In vitro (fibroblast culture) | 10⁻⁹ to 10⁻⁸ M (maximal stimulation); biphasic dose-response | Not specified | in_vitro | Research PMID 1522753 |
| Intracutaneous | 0.5 µg/kg | 30 days (daily) | animal | Research PMID 38345677 |
| Not specified | Various methods and dosages discussed (no single explicit dose stated) | Not specified | human | Research PMID 25302294 |
| Transdermal (microneedle-assisted) | 134 ± 12 nanomoles of peptide and 705 ± 84 nanomoles of copper permeated through microneedle-treated human skin in 9 h (delivery study, not therapeutic dose) | 9 hours (in vitro permeation study) | in_vitro | Research PMID 25690343 |
| Oral (colonic delivery, in vitro model) | 50 mg and 250 mg (microparticle formulation, colonic delivery in vitro) | 4 h release in simulated intestinal fluid; 6 h lag time for colonic tablets | in_vitro | Research PMID 21457130 |
| subcutaneous injection | 1-2 mg | daily · 4-8 weeks | biohackers and anti-aging enthusiasts seeking systemic regenerative or nootropic effects | [Community] |
| subcutaneous injection | 500 mcg | daily · 4-8 weeks | beginners or cautious biohackers starting injectable GHK-Cu | [Community] |
| subcutaneous injection | 2 mg | daily · 4 weeks | experienced biohackers and longevity-focused users stacking GHK-Cu with other peptides | [Community] |
| intranasal | 1 mg | once daily · 4-8 weeks | biohackers and nootropic users seeking cognitive or neuroprotective effects | [Community] |
| intranasal | 500 mcg | once daily · 4-8 weeks | beginners using intranasal GHK-Cu for cognitive or neuroprotective purposes | [Community] |
| subcutaneous injection | 1 mg | every other day (EOD) · 4-8 weeks | biohackers preferring less frequent injection schedules or managing injection site sensitivity | [Community] |
| subcutaneous injection | 1-2 mg | daily · 4-8 weeks | users post-injury or post-surgery seeking soft-tissue and wound healing acceleration | [Community] |
Stacks and blends containing this peptide
All studies (39)
- PMID 15655171 Mixed
Wound healing and skin repair - PMID 16847171 Mixed
Wound healing and skin repair - PMID 26236730 Mixed
Wound healing and skin repair - PMID 28370978 Mixed
Wound healing and skin repair - PMID 29986520 Mixed
Anti-aging and skin rejuvenation (topical/cosmeceutical) - PMID 33938433 Mixed
Anti-aging and skin rejuvenation (topical/cosmeceutical) - PMID 36905132 Mixed
Skeletal muscle dysfunction / COPD-related sarcopenia - PMID 37062921 Mixed
Anti-aging and skin rejuvenation (topical/cosmeceutical) - PMID 37257226 Mixed
Airway remodeling in asthma - PMID 38345677 Mixed
Wound healing and skin repair - PMID 39963574 Mixed
Anti-aging and skin rejuvenation (topical/cosmeceutical) - PMID 42619529 Mixed
Wound healing and skin repair - PMID 42787770 Mixed
Wound healing and skin repair - PMID 1522753
10⁻⁹ to 10⁻⁸ M (maximal stimulation); biphasic dose-response In vitro (fibroblast culture) (in_vitro) - PMID 8747089 In vitro only
Osteoblast biology / bone tissue - PMID 18644225
- PMID 21457130 Animal studies only
Ulcerative colitis / inflammatory bowel disease - PMID 22666519 Animal studies only
Neuroprotection / neurodegenerative disease - PMID 23019153
- PMID 24350846
- PMID 25302294
Various methods and dosages discussed (no single explicit dose stated) Not specified (human) - PMID 25690343
134 ± 12 nanomoles of peptide and 705 ± 84 nanomoles of copper permeated through microneedle-treated human skin in 9 h (delivery study, not therapeutic dose) Tr - PMID 27892491
- PMID 38026438 Animal studies only
Hair growth promotion - PMID 38599632 Animal studies only
Neuroprotection / neurodegenerative disease - PMID 38879894 Animal studies only
Anti-inflammatory and antioxidant effects - PMID 40672369 Animal studies only
Ulcerative colitis / inflammatory bowel disease - PMID 40716276
- PMID 40766919 Animal studies only
Neuroprotection / neurodegenerative disease - PMID 41476424 Animal studies only
Fascia regeneration - PMID 41490200
- PMID 41966639
- PMID 41997403 Animal studies only
Anti-inflammatory and antioxidant effects - PMID 42084774 Animal studies only
Anti-aging (lifespan/longevity models) - PMID 42245779 Animal studies only
Neuroprotection / neurodegenerative disease - PMID 42404628 Animal studies only
Diabetic wound healing - PMID 42510549 Animal studies only
Anti-inflammatory and antioxidant effects - PMID 42578445 Animal studies only
Musculoskeletal conditions (orthopaedic/sports medicine) - PMID 42797253